Kornimate/medical-research-clean huggingface dataset:
optimized antithrombotic therapy of acute myocardial infarction with left ventricular mural thrombus

Conditions: Acute Myocardial Infarction; Left Ventricular Thrombus

Summary: a multi-center study will be done to explore the optimal regimen of antithrombotic therapy for acute myocardial infarction with left ventricular mural thrombus. the investigators will evaluate the different combinations of antiplatelet drugs and anticoagulants for at least one month, such as aspirin 100mg qd+clopidogrel 75mg qd+warfarin (inr1.8-2.2), aspirin 100mg qd+clopidogrel 75mg qd+dabigatran 110mg bid, aspirin 100mg qd+ticagrelor 60mg bid+warfarin (inr1.8-2.2), and aspirin 100mg qd+ticagrelor 60mg bid+dabigatran 110mg bid. transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel 75mg qd/ticagrelor 60mg bid. then the investigators will complete the 12-month follow-up to evaluate the efficacy and safety of the optimal antithrombotic therapy regimen for acute myocardial infarction with left ventricular mural thrombus.


Eligibility criteria:
inclusion criteria: * acute myocardial infarction with left ventricular mural thrombus exclusion criteria: * barc bleedings ≥ 2 * atrial fibrillation * acute stroke or other systemic circulation embolism
effects of sugary drink warning labels

Conditions: Obesity; Diabetes; Weight Gain

Summary: the primary objective of this study is to determine to what degree sugary drink warning labels increase consumers' knowledge about the potential health harms of sugary drinks and reduce sugary drink intake. the study is designed to answer three additional questions: 1) do some warning labels work better than others? 2) what is the effect of warning labels over time? 3) if warning labels influence behavior, is it because they increase knowledge or simply provide a salient reminder that some drinks are less healthy? this study will test the effect of repeated exposure to warning labels on total calories purchased over time and assess whether knowledge or salience better explain label effects.


Eligibility criteria:
inclusion criteria: participants must: * be a primary caregiver of a child under 12 years old; * be ≥18 years old; * read and speak english; * drink sugary drinks at least twelve times per month (\~three times per week) and have a child who does the same * be the primary grocery shopper for their family; * have regular internet access. exclusion criteria: * not a primary caregiver of a child under 12 years old * \<18 years old * cannot read and speak english * does not drink sugary drinks at least 12 times per month and have a child who does the same * is not the primary grocery shopper for their family * does not have regular internet access
reliability of a top mount actuation indicator with levalbuterol mdi in adult and pediatric subjects with asthma or copd

Conditions: Asthma; Chronic Obstructive Pulmonary Disease; COPD

Summary: this is a study to investigate the reliability, ruggedness and safety of the top mounted actuation indicator (tmai) when used with levalbuterol hfa mdi.

this is an open-label, multicenter, tmai study with levalbuterol hfa mdi in adult and pediatric subjects with asthma or copd. period i: one week, open-label, run-in period during which subjects must have asthma or copd symptoms requiring use of, as needed, levalbuterol hfa mdi(without tmai) on at least half of the days \[4-12 actuations on a single day\]. period ii: nine week, open-label period during which subjects will use the levalbuterol hfa mdi with tmai prn. the total study duration for a subject will not exceed 10 weeks. this study was previously posted by sepracor inc. in october 2009, sepracor inc. was acquired by dainippon sumitomo pharma., and in october 2010, sepracor inc's name was changed to sunovion pharmaceuticals inc.

Eligibility criteria:
inclusion criteria: * subject must have a documented diagnosis of asthma or copd for a minimum of 6 months. * subject must have stable baseline asthma or copd and have been using a beta-adrenergic agonist, and/or anti-asthma anti-inflammatory medication, and/or over-the-counter asthma medication for at least 6 months. * subject must be in good health with the exception of their reversible airways disease and not suffering from any chronic condition that might affect their respiratory function. exclusion criteria: * female subject who is pregnant or lactating. * subject who has a history of hospitalization for asthma or copd within 45 days. * subject with currently diagnosed life-threatening asthma or copd, defined as a history of asthma or copd episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 3 months prior. * subject with supplemental oxygen use * subject with a history of cancer * subject with hyperthyroidism, diabetes, hypertension, cardiac diseases, or seizure disorders that currently are not well controlled by medication. * subject with asthma with a greater than 10-pack per year history of cigarette smoking or use of any tobacco products within 6 months.

Keywords: top mounted actuation indicator asthma copd chronic obstructive pulmonary disease
efficacy and safety of quetiapine fumarate (seroquel®) in the treatment of alcohol dependency in patients with bipolar disorder

Conditions: Bipolar I Disorder; Alcohol Dependence

Summary: the purpose of this study is to determine whether treatment with quetiapine fumarate (seroquel) in conjunction with mood stabilizers (lithium or divalproex) for 12 weeks helps patients who have bipolar i disorder with alcohol dependence


Eligibility criteria:
inclusion criteria: * meets criteria for bipolar i disorder with alcohol dependence * outpatient status * recent history of heavy drinking exclusion criteria: * unstable medical illness * recent antipsychotic use * poorly controlled diabetes mellitus or diabetes related illness

Keywords: bipolar i disorder alcohol dependency
mans-nriz trial for covid-19 treatment : extension study

Conditions: COVID-19 Pneumonia

Summary: this search will focus on patients with covid 19 infection this study is a prospective cohort study based on the analysis of response in comparative panel between two arm nitazoxanide, ribavirin and ivermectin plus zinc arm and other arm without any intervention as regards the safety and efficacy and cost effective result. two years duration of the project would be enough to cover the stages of the work as shown below in the time plan. initial stage of collecting materials and patients' clinical data, each patient will undergoes strict follow up period to reveal the clinical, laboratory and radiological response. the procedures are to be approved by the institutional ethical committee.

this search will focus on patients with covid 19 infection this study is a prospective cohort study based on the analysis of response in comparative panel between two arm nitazoxanide, ribavirin and ivermectin plus zinc arm and other arm without any intervention as regards the safety and efficacy and cost effective result. two years duration of the project would be enough to cover the stages of the work as shown below in the time plan. initial stage of collecting materials and patients' clinical data, each patient will undergoes strict follow up period to reveal the clinical, laboratory and radiological response. the procedures are to be approved by the institutional ethical committee.

Eligibility criteria:
inclusion criteria: * aged ≥18 years * laboratory-confirmed sars-cov- 2 infection * hospitalized patients * need reservoir mask for oxygen support * need hfnc for oxygen support exclusion criteria: * mechanical ventilations for oxygen support * inability to take oral medications * pregnancy or breastfeeding
trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer (ibc)

Conditions: Breast Cancer

Summary: study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with ibc

the purpose of this study is to determine whether the addition of nivolumab to chemotherapy improves pathologic complete response (pcr) in the breast and post-therapy lymph nodes evaluated histologically (ypt0/tis ypn0) in patients with inflammatory breast cancer (ibc).

Eligibility criteria:
inclusion criteria: * newly diagnosed inflammatory breast cancer without distant metastases and have not received prior chemotherapy or immunotherapy. all breast cancer subtypes are allowed: triple negative breast cancer (tnbc); hormone receptor (hr)-positive and human epidermal growth factor receptor 2 (her2)-negative; hr-positive or hr-negative and her2-positive exclusion criteria: * clinical or radiologic evidence of distant metastases * malignancy that progressed within the last five years. * cardiac disease (history of and/or active disease) * hiv positive * neuropathy ≥ grade 2, per the nci ctcae v5.0 * allogeneic stem cell or solid organ transplantation * autoimmune disease where in the opinion of the investigator would preclude the use of immunotherapy * idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), or evidence of active pneumonitis * tuberculosis * pregnancy or lactation * treatment with cd137 agonists or immune checkpoint-blockade therapies, including anti-cd40, anti-ctla-4, anti-pd-1, and anti-pd-l1 therapeutic antibodies * treatment with systemic immunosuppressive medications * cardiopulmonary dysfunction * clinically significant history of liver disease, including cirrhosis, autoimmune hepatic disorders, hiv infection, or active hepatitis b or hepatitis c * subject is pregnant or nursing * known hypersensitivity to the components of the study drugs(s)

Keywords: nivolumab
randomized controlled trial on pancreatic stent tube in pancreaticoduodenectomy

Conditions: Pancreatic Cancer; Bile Duct Cancer; Ampullary Cancer; Pancreatitis; Duodenal Cancer

Summary: the purpose of this study is to determine which stent type is effective in the decrease of postoperative stay and complications across pancreaticojejunostomy after pancreaticoduodenectomy.

this study compared the postoperative hospital stay and complications of lost stent with external stent after pancreaticoduodenectomy. the complications of pancreaticoduodenectomy are important to affect the postoperative course, and, a stent tube often places across pancreaticojejunostomy to reduce complications. however, there is no report that demonstrates the postoperative course between pancreatic stent types. we conducted a prospective randomized trial on 100 patients who underwent pancreaticoduodenectomy comparing external stent and lost stent. the primary endpoint was defined as postoperative hospital stay. the secondary endpoints were mortality and morbidity, including pancreatic fistula, delayed gastric emptying, intra-abdominal hemorrhage, and intra-abdominal abscess. patients were recruited into this study before surgery, on the basis of whether pancreatic head resection was anticipated at wmuh for pancreatic head and periampullary disease, and appropriate informed consent was obtained. exclusion criteria was 1) patients with severe complications which were possible to prolong hospital stay, 2) patients who were diagnosed inadequacy for this study by a physician, 3) patients who could not be placed a pancreatic stent tube, and 4) patients without an informed consent.

Eligibility criteria:
inclusion criteria: * on the basis of whether pancreatic head resection was anticipated at wmuh for pancreatic head and periampullary disease, and appropriate informed consent was obtained. exclusion criteria: * patients with severe complications which were possible to prolong hospital stay * patients who were diagnosed inadequacy for this study by a physician * patients who could not be placed a pancreatic stent tube * patients without an informed consent.

Keywords: pancreaticoduodenectomy stent pancreaticojejunostomy hospital stay complication pancreatic fistula
the effect of transcutaneous electrical nerve stimulation on posterior neck pain after thyroidectomy

Conditions: Thyroid Cancer; Neck Pain

Summary: the purpose of tihs study is to determine whether transcutaneous electric nerve stimulation (tens) during thyroidectomy is effective in the reduction of posterior neck pain after thyroidectomy.

thyroidectomy is performed in supine position with the neck fully extended. after thyroidectomy, 80 percent of patients experience posterior neck pain as well as the incision site pain. the posterior neck pain is thought to be due to hyperextension is continued during an average of 90 minutes of surgery. non-steroidal anti-inflammatory agents or opioids are administrated to reduce the pain, but the pain still remained. tens is simple, non-invasive analgesic technique that is used extensively to reduce acute and chronic pain. tens has beneficial effect for the reduction of postoperative pain. the conventional way of administering tens is to use electric characteristics that selectively activate large diameter aβ fiber mediating touch perception without activating smaller diameter aδ and c fiber. in this study, tens during thyroidectomy in posterior neck pain will be evaluated.

Eligibility criteria:
inclusion criteria: * undergoing open total thyroidectomy under general anesthesia * american society of anesthesiology physical status i or ii exclusion criteria: * american society of anesthesiology physical status iii or iv * history of headache or neck pain within six months * past history of herniated cervical disc, cervical foraminal stenosis, ossification of posterior longitudinal ligament

Keywords: transcutaneous electric nerve stimulation thyroidectomy neck pain pain management
health counseling and exercise in patients with acute leukemia - pilot study

Conditions: Acute Leukemia

Summary: the purpose of this pilot study is to test an exercise-based multidimensional intervention for patients with acute leukaemia undergoing consolidation chemotherapy in the context of outpatient management. further, to test for safety, feasibility and preliminary effect on physical and functional capacity, and health related quality of life.


Eligibility criteria:
inclusion criteria: * patients that are able to speak danish \> 18 years and newly diagnosed with acute leukæmia (mds, aml, cmml, apl or all) * normal ekg, blood pressure and pulse * signed informed written consent exclusion criteria: * medical reason that contraindicates physical activity * patients diagnosed with a symptomatic cardiac disease within the last three months. * documented bone metastasis * dementia, psychotic * cannot write or read danish * patients unable to carry out baseline tests

Keywords: cancer related fatigue quality of life psychosocial intervention rehabilitation physical fitness physical activity exercise therapy exercise hematologic hematological leukemia, myeloid, acute acute myeloid leukemia acute lymphoblastic leukemia acute leukemia
reproductive outcomes after a previous episode of tubal ectopic pregnancy in patients managed expectantly and surgically

Conditions: Ectopic Pregnancy

Summary: although ectopic pregnancy was considered a leading cause of first-trimester maternal mortalities, current technological improvements allowed early diagnosis and opened a door for applying less invasive approaches. a tubal pregnancy could be managed either expectantly, medically, or surgically. the expectant management of ectopic pregnancy relies on the fact that a considerable proportion of ectopic gestations terminate by spontaneous tubal abortion. this approach is usually kept for stable cases with a small gestational sac and low beta-human chorionic gonadotropin (beta-hcg) serum levels. for hemodynamically unstable patients, higher levels of beta-hcg, and larger gestational sacs, surgery is often considered as the treatment of choice (16). considering this background, the study aims to analyze the subsequent natural reproductive outcomes of patients that had a previous tubal ectopic pregnancy and were managed either expectantly or surgically. moreover, it amis to determine the factors that could influence the fertility potential of these patients in each treatment group.


Eligibility criteria:
inclusion criteria: * women with one episode of tubal ectopic pregnancy, treated by expectant management, salpingectomy, or salpingostomy; * for patients treated surgically, only patients with at least one patent fallopian tube confirmed via postoperative hysterosalpingography were included in the analysis. exclusion criteria: * pregnancies of unknown location * other types of ectopic pregnancy * pelvic inflammatory disease * pelvic adhesions * intrauterine pathologies * pregnancies obtained after assisted-reproductive technologies (art)

Keywords: ectopic pregnancy expectant management pregnancy outcome salpingectomy salpingostomy
gut microbes and metabolic group in different pbc patients for udca response

Conditions: Primary Biliary Cirrhosis

Summary: to compare intestinal flora diversity in different pbc patients with udca responses, and further study the differences of bile acid metabolism and short chain fatty acid metabolism in feces and serum of two groups of pbc patients.

the pbc patients have been enrolled in the study for udca treatment more than 1 year, who is divided into the udca total response group and the other poor response group according to paris-i/ii standard .the feces of two groups of patients were collected and the differences of microbial polymorphism of fecal microorganism in two groups were observed. the metabolic differences of bile acids and short chain fatty acids in serum and feces of two groups of pbc patients were studied by means of metabolic proteomics.

Eligibility criteria:
inclusion criteria: 1.confirmed diagnostic criteria about pbc, and orally udca treatment for more than a year; 2.30-70 years old; 3.currently only udca therapy, not glucocorticoids and immunosuppressor treatment. exclusion criteria: 1. viral liver disease; 2. alcoholic liver disease; 3. fatty liver; 4. drug-associated liver damage; 5. infectious disease; 6. obesity; 7. gastrointestinal diseases; 8. combined with other autoimmune diseases; 9. cardiac and pulmonary dysfunction; 10. renal dysfunction, malignant tumor,; 11. neurological and psychiatric abnormalities; 12. nearly 2 months to take antibiotics and probiotics; 13. nearly 3 months participate in other drug clinical trials .
efficacy, safety, and tolerability of selonsertib (gs-4997) in participants with diabetic kidney disease

Conditions: Diabetic Kidney Disease

Summary: the primary objective of this study is to determine the effect of selonsertib (formerly gs-4997) on estimated glomerular filtration rate (egfr) decline in participants with diabetic kidney disease (dkd). participants will be randomized with a 1:1:1:1 allocation to receive 1 of 3 doses of selonsertib (2 mg, 6 mg, or 18 mg) or matching placebo.


Eligibility criteria:
key inclusion criteria: * adult male or females with prior diagnosis of diabetic kidney disease * type 2 diabetes mellitus diagnosis for at least 6 months * egfr (mdrd) at screening ≥ 15 ml/min/1.73m\^2 to \< 60 ml/min/1.73m\^2 * urine albumin to creatinine ratio (uacr) as follows: * stage/stratum 3a: egfr range 45 to \< 60 ml/min; uacr ≥ 600 mg/g * stage/stratum 3b: egfr range 30 to \< 45 ml/min; uacr ≥ 300 mg/g * stage/stratum 4: egfr range 15 to \< 30 ml/min; uacr ≥ 150 mg/g * receiving angiotensin-converting-enzyme inhibitor (acei) or angiotensin receptor blockers (arb) at a minimum dose deemed appropriate for the individual by the investigator and be at a stable dose for the last three months * individuals not on acei/arb may be screened if there is documented intolerance to ace inhibitor and/or arb key exclusion criteria: * type 1 diabetes mellitus * hba1c \> 9.5% * non-diabetic kidney disease * uacr \> 5000 mg/g on any measurement during screening * end stage renal disease (esrd; receiving peritoneal dialysis, hemodialysis, or status post renal transplantation) or anticipated to occur within the treatment period * unstable cardiovascular disease * pregnant or lactating females note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: diabetic kidney disease gilead
local vibration in multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: gastrocnemius spasticity is one of the main complaints in multiple sclerosis patients.local muscle vibration is a method used for spasticity inhibition. however, when the studies in the literature are examined; it is noted that local vibration applications for spasticity are usually single sessions and evaluate the acute effect, do not produce functional outputs, there is no consensus on frequency and amplitude and the changes in muscle architecture are not examined. in this study, we aimed to investigate the effect of local vibration applied on spastic gastrocnemius on muscle architectural and functional properties in multiple sclerosis patients in addition to the standard physiotherapy program. the study was planned to include 3 groups, 2 treatment and 1 control group. the control group will receive standard physiotherapy, one of the treatment groups will receive 50 hz local vibration in addition to standard physiotherapy, and other treatment group will receive 100 hz local vibration in addition to standard physiotherapy. disease severity, gastrocnemius spasticity, architectural and viscoelastic properties of muscle, ankle proprioception, balance and gait skills will be evaluated before and after 8 weeks treatment program. as a result; effectiveness of local vibration in addition to standard physiotherapy program and whether there is a difference between applications at different frequencies will be examined.


Eligibility criteria:
inclusion criteria: * \> 18 years * edss\<5,5 * gastrocnemius spasticity\<2 exclusion criteria: * having any injury or surgery of the lower extremity * having systemic and metabolic disease * having behavioral and cognitive problems that prevent consistence to guidelines given

Keywords: multiple sclerosis spasticity local vibration muscle architecture functionality
pictorial representation of illness and self measure

Conditions: Rheumatoid Arthritis

Summary: prism (pictorial representation of illness and self measure) has been developed since the mid-1990s; the task was first developed as a simple measure of how a person was coping with his or her experience of illness. this is an international, multicentre study to evaluate the prism tool for the assessment of suffering in rheumatoid arthritis at different stages of the illness and the effect of treatment intervention. there are 5 sites: berlin, oxford, limoges, montreal and queensland. the study will recruit 200 patients in total. in addition to the procedures for the patient's routine clinical visit, the patients will be invited to answer a series of questionnaires and donate 20ml blood sample. patients will be asked to attend 3 times over 24 weeks


Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study. * male or female, aged 18 years or above. * written confirmed diagnosed of rheumatoid arthritis exclusion criteria: * a diagnosis of any of the following: * multiple sclerosis * motor neurone disease * parkinson's disease * alzheimer's disease * depression or anxiety disorders as identified using the patient depression screening questions from the patient health questionnaire 9 (phq9).